Table 2.
Demographics and baseline characteristics by sarcopenia status
| Variable | Limited Definitions |
|||||
|---|---|---|---|---|---|---|
| EWGSOP2 |
FNIH |
Lowest Quartile |
||||
| Nonsarcopenic | Sarcopenic | Nonsarcopenic | Sarcopenic | Nonsarcopenic | Sarcopenic | |
| Number of subjects | 366 | 58 | 372 | 52 | 320 | 104 |
| Age, yr | 57.9 (11.9) | 53.7 (14.2) | 57.1 (12.5) | 59.1 (10.2) | 58.2 (11.9) | 54.7 (12.9) |
| Sex, F | 170 (46.4) | 27 (46.6) | 181 (48.7) | 16 (30.8) | 150 (46.9) | 47 (45.2) |
| Race | ||||||
| White | 292 (79.8) | 34 (58.6) | 293 (78.8) | 33 (63.5) | 261 (81.6) | 65 (62.5) |
| Black | 27 (7.4) | 2 (3.4) | 29 (7.8) | 0 (0) | 24 (7.5) | 5 (4.8) |
| Asian | 21 (5.7) | 14 (24.1) | 26 (7.0) | 9 (17.3) | 18 (5.6) | 17 (16.3) |
| Other | 26 (7.1) | 8 (13.8) | 24 (6.5) | 10 (19.2) | 17 (5.3) | 17 (16.3) |
| Hispanic | 51 (13.9) | 15 (25.9) | 46 (12.4) | 20 (38.5) | 37 (11.6) | 29 (27.9) |
| Disease diagnosis* | ||||||
| COPD | 73 (19.9) | 12 (20.7) | 80 (21.5) | 5 (9.6) | 64 (20.0) | 21 (20.2) |
| PAH | 22 (6.0) | 2 (3.4) | 21 (5.6) | 3 (5.8) | 18 (5.6) | 6 (5.8) |
| CF | 24 (6.6) | 8 (13.8) | 32 (8.6) | 0 (0) | 19 (5.9) | 13 (12.5) |
| IPF | 247 (67.5) | 36 (62.1) | 239 (64.2) | 44 (84.6) | 219 (68.4) | 64 (61.5) |
| BMI, kg/m2 | 26.8 (4.2) | 21.4 (3.5) | 25.7 (4.5) | 28.1 (3.6) | 27.2 (4.1) | 22.4 (3.6) |
| SF12-PCS | 27.2 (9.3) | 26.0 (9.3) | 27.1 (9.5) | 26.4 (8.4) | 27.1 (9.3) | 27.0 (9.4) |
| 6MWD, m | 280 [175–366] | 203 [109–298] | 279 [175–366] | 200 [110–298] | 278 [179–366] | 246 [127–324] |
| LAS | 42.8 (13.9) | 48.5 (18.8) | 42.9 (14.5) | 48.3 (16.1) | 42.4 (13.1) | 47.1 (18.5) |
| SPPB score | 9.9 (2.7) | 8.3 (3.9) | 9.8 (2.9) | 9.3 (3.1) | 10.0 (2.6) | 8.9 (3.6) |
| Trails B Test score | 92 [69–119] | 104 [76–139] | 92 [69–119] | 109 [76–141] | 88 [68–115] | 106 [77–142] |
| SF12-MCS | 48.1 (10.7) | 48.8 (13.4) | 47.9 (11.0) | 50.2 (11.5) | 48.1 (10.7) | 48.2 (12.1) |
| Variable |
Expanded Definitions |
|||||
|
EWGSOP2 |
FNIH |
Lowest Quartile |
||||
| Nonsarcopenic | Sarcopenic | Nonsarcopenic | Sarcopenic | Nonsarcopenic | Sarcopenic | |
| Number of subjects | 367 | 36 | 378 | 25 | 353 | 50 |
| Age, yr | 57.5 (12.1) | 56.6 (12.2) | 57.2 (12.4) | 61.0 (6.8) | 57.4 (12.1) | 57.5 (12.6) |
| Sex, F | 169 (46.0) | 19 (52.8) | 177 (46.8) | 11 (44.0) | 166 (47.0) | 22 (44.0) |
| Race | ||||||
| White | 292 (79.6) | 19 (52.8) | 297 (78.6) | 14 (56.0) | 282 (79.9) | 29 (58.0) |
| Black | 24 (6.5) | 2 (5.6) | 26 (6.9) | 0 (0) | 25 (7.1) | 1 (2.0) |
| Asian | 25 (6.8) | 7 (19.4) | 27 (7.1) | 5 (20.8) | 23 (6.5) | 9 (18.0) |
| Other | 26 (7.1) | 8 (22.2) | 28 (7.4) | 6 (24.0) | 23 (6.5) | 11 (22.0) |
| Hispanic | 53 (14.4) | 11 (30.6) | 54 (14.4) | 8 (33.3) | 48 (13.6) | 16 (32.0) |
| Disease diagnosis* | ||||||
| COPD | 76 (20.7) | 7 (19.4) | 80 (21.2) | 3 (12.0) | 75 (21.2) | 8 (16.0) |
| PAH | 23 (6.3) | 1 (2.8) | 23 (6.1) | 1 (4.0) | 22 (6.2) | 2 (4.0) |
| CF | 27 (7.4) | 3 (8.3) | 30 (7.9) | 0 (0) | 27 (7.6) | 3 (6.0) |
| IPF | 241 (65.7) | 25 (69.4) | 245 (64.8) | 21 (84.0) | 229 (64.9) | 37 (74.0) |
| BMI, kg/m2 | 26.5 (4.4) | 21.6 (3.6) | 25.9 (4.5) | 27.5 (4.2) | 26.5 (4.4) | 22.6 (3.8) |
| SF12-PCS | 27.3 (9.4) | 25.8 (9.0) | 27.2 (9.5) | 26.8 (8.2) | 27.4 (9.5) | 26.0 (8.3) |
| 6MWD, m | 283 [183–367] | 185 [100–276] | 282 [182–366] | 175 [93–226] | 282 [183–366] | 198 [119–312] |
| LAS | 41.7 (12.3) | 48.2 (16.7) | 41.7 (12.4) | 50.9 (16.4) | 41.5 (11.9) | 48.2 (17.5) |
| SPPB score | 10.0 (2.7) | 7.8 (3.8) | 9.9 (2.8) | 8.4 (3.4) | 10.1 (2.7) | 8.1 (3.6) |
| Trails B Test score | 92 [69–119] | 105 [85–144] | 92 [69–118] | 117 [95–157] | 90 [69–117] | 110 [81–150] |
| SF12-MCS | 48.2 (10.8) | 47.6 (12.7) | 48.2 (11.0) | 47.8 (11.8) | 48.2 (11.1) | 48.4 (10.7) |
Definition of abbreviations: 6MWD = 6-minute walk distance; BMI = body mass index; CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; EWGSOP2 = European Working Group on Sarcopenia in Older People 2; FNIH = Foundation for the National Institutes of Health; IPF = idiopathic pulmonary fibrosis; IQR = interquartile range; LAS = Lung Allocation Score (measured at time of body composition assessment); Lowest Quartile = distribution-based lowest quartile of sarcopenic study participants; PAH = pulmonary arterial hypertension; SF12-MCS = Short Form 12 Mental Health Composite Score; SF12-PCS = Short Form 12 Physical Health Composite Score; SPPB = Short Physical Performance Battery.
Data are presented as n (%), mean ± SD, or median [IQR].
Disease diagnoses used for calculation of LAS.